The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase
- PMID: 12869391
- DOI: 10.1161/01.RES.0000086943.72932.71
The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase
Abstract
Trimetazidine acts as an effective antianginal clinical agent by modulating cardiac energy metabolism. Recent published data support the hypothesis that trimetazidine selectively inhibits long-chain 3-ketoacyl CoA thiolase (LC 3-KAT), thereby reducing fatty acid oxidation resulting in clinical benefit. The aim of this study was to assess whether trimetazidine and ranolazine, which may also act as a metabolic modulator, are specific inhibitors of LC 3-KAT. We have demonstrated that trimetazidine and ranolazine do not inhibit crude and purified rat heart or recombinant human LC 3-KAT by methods that both assess the ability of LC 3-KAT to turnover specific substrate, and LC 3-KAT activity as a functional component of intact cellular beta-oxidation. Furthermore, we have demonstrated that trimetazidine does not inhibit any component of beta-oxidation in an isolated human cardiomyocyte cell line. Ranolazine, however, did demonstrate a partial inhibition of beta-oxidation in a dose-dependent manner (12% at 100 micromol/L and 30% at 300 micromol/L). Both trimetazidine (10 micromol/L) and ranolazine (20 micromol/L) improved the recovery of cardiac function after a period of no flow ischemia in the isolated working rat heart perfused with a buffer containing a relatively high concentration (1.2 mmol/L) of free fatty acid. In summary, both trimetazidine and ranolazine were able to improve ischemic cardiac function but inhibition of LC 3-KAT is not part of their mechanism of action. The full text of this article is available online at http://www.circresaha.org.
Comment in
-
Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.Circ Res. 2003 Aug 8;93(3):e33-7. doi: 10.1161/01.RES.0000086964.07404.A5. Epub 2003 Jul 17. Circ Res. 2003. PMID: 12869392
Similar articles
-
Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.Circ Res. 2003 Aug 8;93(3):e33-7. doi: 10.1161/01.RES.0000086964.07404.A5. Epub 2003 Jul 17. Circ Res. 2003. PMID: 12869392
-
The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.Circ Res. 2000 Mar 17;86(5):580-8. doi: 10.1161/01.res.86.5.580. Circ Res. 2000. PMID: 10720420
-
The effects of chronic trimetazidine treatment on mechanical function and fatty acid oxidation in diabetic rat hearts.Can J Physiol Pharmacol. 2007 May;85(5):527-35. doi: 10.1139/y07-036. Can J Physiol Pharmacol. 2007. PMID: 17632588
-
Optimizing cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated?Coron Artery Dis. 2001 Feb;12 Suppl 1:S8-11. Coron Artery Dis. 2001. PMID: 11286307 Review.
-
Cardioprotective effects of trimetazidine: a review.Curr Med Res Opin. 2003;19(7):661-72. doi: 10.1185/030079903125002261. Curr Med Res Opin. 2003. PMID: 14606990 Review.
Cited by
-
New directions in the treatment of heart failure: targeting free fatty acid oxidation.Curr Heart Fail Rep. 2007 Dec;4(4):236-242. doi: 10.1007/s11897-007-0018-1. Curr Heart Fail Rep. 2007. PMID: 18221621 Review.
-
Trimetazidine protects retinal ganglion cells from acute glaucoma via the Nrf2/Ho-1 pathway.Clin Sci (Lond). 2017 Sep 3;131(18):2363-2375. doi: 10.1042/CS20171182. Print 2017 Sep 15. Clin Sci (Lond). 2017. PMID: 28811386 Free PMC article.
-
Deranged Cardiac Metabolism and the Pathogenesis of Heart Failure.Card Fail Rev. 2016 May;2(1):8-13. doi: 10.15420/cfr.2016:5:2. Card Fail Rev. 2016. PMID: 28785448 Free PMC article.
-
Trimetazidine does not alter metabolic substrate oxidation in cardiac mitochondria of target patient population.Br J Pharmacol. 2016 May;173(9):1529-40. doi: 10.1111/bph.13454. Epub 2016 Mar 6. Br J Pharmacol. 2016. PMID: 26844527 Free PMC article.
-
Mitochondria-mediated cardioprotection by trimetazidine in rabbit heart failure.J Mol Cell Cardiol. 2013 Jun;59:41-54. doi: 10.1016/j.yjmcc.2013.01.016. Epub 2013 Feb 4. J Mol Cell Cardiol. 2013. PMID: 23388837 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources